Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome

This publication has 27 references indexed in Scilit:

• Decreases in Ovarian Cytochrome P450c17α Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary Syndrome
  New England Journal of Medicine, 1996
• Factors Responsible for Impaired Fibrinolysis in Obese Subjects and NIDDM Patients
  Diabetes, 1994
• Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide and plasminogen activator inhibitor-1
  The American Journal of Cardiology, 1993
• The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance
  Metabolism, 1993
• Risk Factors for Coronary Artery Disease in Healthy Persons with Hyperinsulinemia and Normal Glucose Tolerance
  New England Journal of Medicine, 1989
• Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.
  Heart, 1988
• PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
  The Lancet, 1987
• Plasminogen activator inhibitors
  Blood, 1987
• Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects
  Metabolism, 1986
• Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial Infarction
  New England Journal of Medicine, 1985